GLB1 and Marchiafava-Bignami disease: The laboratory diagnostics of MBD is based on measurement of the β-GAL activity in blood cells and detection of keratan sulfate in plasma and urine by the Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) method, followed by identification of biallelic variants in the GLB1 gene.